Regulatory responses to the global pandemic: what next for life sciences companies?. Laura Orlando, Martina Maffei, Frederic Chevallier, Lourdes Fraguas, Ina vom Feld, Jonathan Turnbull
The fight against Covid-19 has prompted governments from around the world to adopt a series of measures, such as, the surveillance of citizens through smartphones both to identify and halt the proliferation of the disease and avoid overloading public health services. While this type of government surveillance is nothing new, debates about data protection have increased around the world. Despite numerous challenges regarding data protection in Brazil.
The outbreak of the coronavirus’ has posed unprecedented challenges to healthcare systems worldwide. The Federal Republic of Germany has adopted a series of drastic measures aimed at containing the spread of Covid-19. These measures are currently being eased gradually as the number of infections declines. This article provides an overview of past and current legislative healthcare measures, which are of particular importance for inpatient care providers.
The article provides an introduction to recently issued guidelines on telemedicine in India, and summarises the various provisions included in the relationship between doctors and their patients.
Code Blue: the constitutional model in Pakistan calls for CPR
Mexican lawyers respond to populist government’s shortages of medical products and services
Covid-19: the Belgian perspective
Regulatory responses to health emergencies and product shortages during the Covid-19 pandemic in Brazil
Uruguay: telemedicine and Covid-19
The Royalty Pharma case: SPCs and the role of independent inventive activity
Brazil has been using digital health as a tool to contain the Covid-19 outbreak. The present article comprises a summary of the regulatory highlights related to digital health in Brazil, which were driven by the pandemic scenario, such as: telemedicine, medical prescriptions and medical certificates in digital form; and remote sale and home delivery of medicines subject to special control.
Digital practices and the related use of personal data are now at the heart of many projects in the healthcare sector, and the Covid-19 crisis has had a boosting effect on this phenomenon. A key question is how to use such data for secondary purposes, including for sake of health research? Under French law, such re-use is possible, subject to a strict protection of personal data and the privacy of individuals.
In Sweden, the Covid-19 pandemic has so far had a significant impact on the provision of Swedish healthcare. Reports are made of major increases in the use of telemedical services and doctors are seeing their patients remotely to a much greater extent than before – all for the purpose of limiting exposure and spread of the coronavirus. Virtual clinical trials are also emerging, enabling remote medical services not only in clinical practice but also in clinical research.
Digital health in Brazil during the Covid-19 outbreak
Changing the product range – opportunity or necessity in times of Covid-19?
Remote clinical trials: from emergency to new normal
The coexistence of public and private healthcare sectors and the impact caused by overloaded hospital beds: the effects of Covid-19 on the Brazilian healthcare system
The impacts of Covid-19 on access to private healthcare in Brazil
Confidentiality of personal data related to health in the framework of an employment relationship in the context of Covid-19
In December 2019 the Brazilian Board of Health published a new resolution creating a new regulatory procedure for companies to import and commercialise Cannabis products, a topic that has been under a lot of discussion in Brazil. This article analyses the new regulation.
This webcast and audience Q&A with Paul Rawlinson, Global Chairman of Baker McKenzie, covered law firm strategy and culture, as well as topical issues such as the potential effects of Brexit and a Trump presidency
This webcast and audience Q&A with Funke Abimbola, General Counsel of Roche UK, explored the corporate compliance challenges facing the leading biotech company and the evolving role of in-house lawyers.
The interview examined the legal aspects of supporting Roche’s pharmaceutical R&D and healthcare strategies, addressing issues such as company operations, risk management, and diversity in the profession. The interview was conducted by the BBC's Sally Bundock.